



1220 Old Alpharetta Road, Suite 300
Alpharetta, GA 30005
www.clearsidebio.com



Fast Facts

Founders:	Henry Edelhauser, Samirkumar Patel, Mark Prausnitz, Vladimir Zamitsyn
Date Founded:	2011
Employees:	18
Headquarters:	Alpharetta, GA
Revenue:	N/A
University:	Emory University, Georgia Institute of Technology
Federal Funding Agency:	National Institutes of Health
Initial Research Funding:	\$1.6M

Clearside Biomedical, Inc. is an ophthalmic pharmaceutical company developing technologies to improve drug delivery to the eye to treat diseases that threaten sight. The microinjection platform supplies drugs to a targeted section of the eye — the suprachoroidal space between the choroid and sclera, allowing eye care professionals to treat patients in their offices without complicated surgical techniques. Clearside Biomedical's initial studies testing this delivery method are showing encouraging results. The company was established through a \$4 million investment from Hatteras Venture Partners, Georgia Research Alliance and Kenan Flagler Venture Fund. In 2013 the company received additional funding of \$7.9 million from Santen Pharmaceuticals Co., Ltd in Osaka, Japan and Mountain Group Capital.

The Story Behind the Company

The technology at the center of Clearside Biomedical is the result of a multiyear collaboration between Henry Edelhauser of the Emory University School of Medicine and Mark Prausnitz of the Georgia Institute of Technology. In contrast to standard intravitreal injections, their microneedle technology provides a more targeted approach for the treatment of retinal diseases, improves the effectiveness of the drug by confining it to the site of the disease, and reduces side effects that can occur when the drug enters other parts of the eye. Co-founder Dr. Samirkumar Patel completed his doctoral degree at Georgia Tech in the drug delivery lab of Dr. Prausnitz.

Federal grants awarded to Emory University from the National Institutes of Health (NIH) supported their work.



3350 Riverwood Parkway, Suite 1927

Atlanta, GA 30339

www.inhibikase.com



Fast Facts

Founders:	Daniel Kalman
Date Founded:	2010
Employees:	2
Headquarters:	Atlanta, GA
Revenue:	N/A
University:	Emory University
Funding Agency:	National Institutes of Health (National Institute of Allergy and Infectious Diseases)
Initial Research Funding:	\$2.1M

Inhibikase Therapeutics is a biopharmaceutical company developing host-targeted antiviral therapeutics to treat and prevent infectious diseases including polyoma virus-based diseases.

The company focuses on compounds that can be used to target a variety of diseases based on a common mechanism: the inhibition of certain cellular kinase pathways. The company has received FDA approval for a phase II trial in progressive multifocal leukoencephalopathy (PML) caused by the JC virus.

The Story Behind the Company

Inhibikase was founded based on Emory technology from Daniel Kalman, Ph.D. Dr. Kalman is an associate professor in the Emory School of Medicine Department of Pathology and Laboratory Medicine. Dr. Kalman's lab is focused on understanding how bacterial and viral pathogens interface with the host. His lab was the first to demonstrate that inhibition of non-receptor host tyrosine kinases can block replication and propagation of certain types of viruses in animals.

Dr. Kalman received his Ph.D. at University of California, Los Angeles and trained under Nobel Laureate Michael Bishop at University of California, San Francisco in virology before opening his own laboratory at Emory University in 2001. He is the scientific founder of the company and continues to work on technology in host-targeted antivirals.

Federal grants awarded to Emory University from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, partially funded the research leading to these inventions.